When they need a proven partner for levodopa
CONSIDER XADAGO NEXT

When they need a proven
partner for levodopa
CONSIDER XADAGO NEXT

Not actual patient. Used for
illustrative purposes.

Why XADAGO now?

Levodopa has limitations over time
Despite its efficacy, the therapeutic window
of levodopa narrows over time1,2

Chart showing the therapeutic window of levodopa over time.

Inconsistent levodopa response increases the need for adjunctive treatment options3

Mechanism of Action

XADAGO is a highly selective inhibitor of monoamine oxidase B (MAO-B)4,5

  • XADAGO has over 1000-fold greater selectivity for MAO-B over MAO-A4
  • The precise mechanism by which XADAGO exerts its effects in Parkinson’s disease (PD) is unknown4
Digital illustration showing XADAGO blocking the breakdown of dopamine in the brain.

Identifying XADAGO patients

These profiles represent patients who may be appropriate for treatment with XADAGO.

Michael, 57-year-old male, shop owner

18100_XADAGO_HCP_Why_Michael

Not actual patient. Used for

illustrative purposes.

PATIENT HISTORY

First noticed right-hand tremor at age 55 and was diagnosed with PD a year later. He was initially started on a dopamine agonist but did not tolerate due to side effects—sometimes he would feel dizzy or more tired. He tolerated the change to carbidopa/levodopa 25/100 mg three times a day with good response.

CURRENT STATUS

About 1 year after starting carbidopa/levodopa, patient notes increased slowness, rigidity, and tremor with the current dose of carbidopa/levodopa. The symptoms are interfering with his work around the shop.

See how XADAGO can help patients experiencing motor fluctuations

Celia, 62-year-old female, part-time accountant

18100_XADAGO_HCP_Why_Celia

Not actual patient. Used for

illustrative purposes.

PATIENT HISTORY

Diagnosed with PD 4 years ago, Celia had improved motor function with carbidopa/levodopa (25 mg/100 mg) three times a day and pramipexole extended release 2.25 mg.

CURRENT STATUS

Now she is experiencing her carbidopa/levodopa dose wearing off sooner than previously. About 30-45 minutes before each dose, she notes increased tremor and balance difficulty. She is unable to increase her pramipexole due to lower-extremity edema at higher doses. The off time impairs her work as a part-time accountant.

Learn about improving on time—without troublesome dyskinesia

NEXT: XADAGO efficacy

XADAGO co-pay program LEARN MORE

References

1. Hickey P, Stacy M. Available and emerging treatments for Parkinson’s disease: a review. Drug Des Devel Ther. 2011(5):241-254. 2. Jankovic J. Motor fluctuations and dyskinesias in Parkinson’s disease: clinical manifestations. Mov Disord. 2005;20(Suppl 11):S11-S16. 3. Lewis SJ, Foltynie T, Blackwell AD, Robbins TW, Owen AM, Barker RA. Heterogeneity of Parkinson’s disease in the early clinical stages using a data driven approach. J Neurol Neurosurg Psychiatry. 2005;76(3):343-348. 4. XADAGO. Package Insert. US WorldMeds, LLC. 5. Onofrj M, Bonanni L, Thomas A. An expert opinion on safinamide in Parkinson’s disease. Expert Opin Investig Drugs. 2008;17(7):1115-1125.

IMPORTANT SAFETY INFORMATION

INDICATION

  • XADAGO (safinamide) is indicated as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease (PD) experiencing “off” episodes.

IMPORTANT SAFETY INFORMATION FOR HEALTHCARE PROVIDERS

CONTRAINDICATIONS

  • Concomitant use of other drugs in the monoamine oxidase inhibitor (MAOI) class or other drugs that are potent inhibitors of monoamine oxidase, including linezolid.
  • Concomitant use of opioid drugs (e.g., meperidine and its derivatives, methadone, propoxyphene, or tramadol); serotonin-norepinephrine reuptake inhibitors (SNRIs), tri- or tetra-cyclic or triazolopyridine antidepressants; cyclobenzaprine; methylphenidate, amphetamine, and their derivatives; or St. John’s wort. Concomitant use could result in life-threatening serotonin syndrome.
  • Concomitant use of dextromethorphan.
  • In patients with a history of a hypersensitivity to safinamide.
  • In patients with severe hepatic impairment (Child-Pugh C).

WARNINGS & PRECAUTIONS

  • XADAGO may cause or exacerbate hypertension. In clinical trials, the incidence of hypertension was 7%, 5%, and 4% for XADAGO 50mg, 100mg, and placebo respectively. Patients should be monitored after starting XADAGO for new-onset hypertension or hypertension that is not adequately controlled. Dietary tyramine restriction is not required during treatment with recommended doses of XADAGO. However, patients should be advised to avoid foods containing a very high amount of tyramine because of the potential for severe increases in blood pressure, also referred to as hypertensive urgency, crisis, or emergency.
  • Patients treated with dopaminergic medications have reported falling asleep while engaged in activities of daily living. If a patient develops daytime sleepiness or episodes of falling asleep during activities that require full attention (e.g., driving a motor vehicle, conversations, eating), XADAGO should ordinarily be discontinued, or the patient should be advised to avoid driving and other potentially dangerous activities.
  • May cause dyskinesia (or exacerbate dyskinesia).
  • Patients with a major psychotic disorder should ordinarily not be treated with XADAGO because of the risk of exacerbating psychosis with an increase in central dopaminergic tone. Consider dosage reduction or discontinuation if hallucinations or psychotic-like behavior develop.
  • Patients can experience impulse control/compulsive behaviors while taking XADAGO. Because patients may not recognize these behaviors as abnormal, it is important for prescribers to specifically ask patients or their caregivers about new or increased abnormal behaviors.
  • Withdrawal-emergent hyperpyrexia and confusion, a symptom complex resembling neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with rapid dose reduction, withdrawal of, or changes in drugs that increase central dopaminergic tone.
  • Monitor periodically for visual changes in patients with a history of retinal/macular degeneration, uveitis, inherited retinal conditions, family history of hereditary retinal disease, albinism, retinitis pigmentosa, or any active retinopathy (e.g., diabetic retinopathy).

DOSING GUIDELINES & CONSIDERATIONS

  • The maximum recommended dosage of XADAGO in patients with moderate hepatic impairment is 50 mg once daily. Discontinue XADAGO if patient progresses from moderate to severe hepatic impairment. XADAGO is contraindicated in patients with severe hepatic impairment.

ADVERSE REACTIONS

  • In placebo-controlled studies, the most common adverse reactions associated with XADAGO treatment in which the incidence for XADAGO 100mg/day was at least 2% greater than the incidence for placebo were dyskinesia, fall, nausea, and insomnia.

To report SUSPECTED ADVERSE REACTIONS or product complaints, contact Supernus Pharmaceuticals, Inc. at 1-888-492-3246 (1-888-4XADAGO). You may also report SUSPECTED ADVERSE REACTIONS to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information and Patient Information.

IMPORTANT SAFETY INFORMATION

INDICATION

  • XADAGO (safinamide) is indicated as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease (PD) experiencing “off” episodes.

IMPORTANT SAFETY INFORMATION FOR HEALTHCARE PROVIDERS

CONTRAINDICATIONS

  • Concomitant use of other drugs in the monoamine oxidase inhibitor (MAOI) class or other drugs that are potent inhibitors of monoamine oxidase, including linezolid.
  • Concomitant use of opioid drugs (e.g., meperidine and its derivatives, methadone, propoxyphene, or tramadol); serotonin-norepinephrine reuptake inhibitors (SNRIs), tri- or tetra-cyclic or triazolopyridine antidepressants; cyclobenzaprine; methylphenidate, amphetamine, and their derivatives; or St. John’s wort. Concomitant use could result in life-threatening serotonin syndrome.
  • Concomitant use of dextromethorphan.
  • In patients with a history of a hypersensitivity to safinamide.
  • In patients with severe hepatic impairment (Child-Pugh C).

WARNINGS & PRECAUTIONS

  • XADAGO may cause or exacerbate hypertension. In clinical trials, the incidence of hypertension was 7%, 5%, and 4% for XADAGO 50mg, 100mg, and placebo respectively. Patients should be monitored after starting XADAGO for new-onset hypertension or hypertension that is not adequately controlled. Dietary tyramine restriction is not required during treatment with recommended doses of XADAGO. However, patients should be advised to avoid foods containing a very high amount of tyramine because of the potential for severe increases in blood pressure, also referred to as hypertensive urgency, crisis, or emergency.
  • Patients treated with dopaminergic medications have reported falling asleep while engaged in activities of daily living. If a patient develops daytime sleepiness or episodes of falling asleep during activities that require full attention (e.g., driving a motor vehicle, conversations, eating), XADAGO should ordinarily be discontinued, or the patient should be advised to avoid driving and other potentially dangerous activities.
  • May cause dyskinesia (or exacerbate dyskinesia).
  • Patients with a major psychotic disorder should ordinarily not be treated with XADAGO because of the risk of exacerbating psychosis with an increase in central dopaminergic tone. Consider dosage reduction or discontinuation if hallucinations or psychotic-like behavior develop.
  • Patients can experience impulse control/compulsive behaviors while taking XADAGO. Because patients may not recognize these behaviors as abnormal, it is important for prescribers to specifically ask patients or their caregivers about new or increased abnormal behaviors.
  • Withdrawal-emergent hyperpyrexia and confusion, a symptom complex resembling neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with rapid dose reduction, withdrawal of, or changes in drugs that increase central dopaminergic tone.
  • Monitor periodically for visual changes in patients with a history of retinal/macular degeneration, uveitis, inherited retinal conditions, family history of hereditary retinal disease, albinism, retinitis pigmentosa, or any active retinopathy (e.g., diabetic retinopathy).

DOSING GUIDELINES & CONSIDERATIONS

  • The maximum recommended dosage of XADAGO in patients with moderate hepatic impairment is 50 mg once daily. Discontinue XADAGO if patient progresses from moderate to severe hepatic impairment. XADAGO is contraindicated in patients with severe hepatic impairment.

ADVERSE REACTIONS

  • In placebo-controlled studies, the most common adverse reactions associated with XADAGO treatment in which the incidence for XADAGO 100mg/day was at least 2% greater than the incidence for placebo were dyskinesia, fall, nausea, and insomnia.

To report SUSPECTED ADVERSE REACTIONS or product complaints, contact Supernus Pharmaceuticals, Inc. at 1-888-492-3246 (1-888-4XADAGO). You may also report SUSPECTED ADVERSE REACTIONS to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information and Patient Information.